Pneumococcal vaccine and opsonic pneumococcal antibody.

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Streptococcus pneumoniae causes significant pneumonia and invasive diseases.
• Pneumococcal conjugate vaccines have reduced disease incidence.
• New vaccine trials cannot use placebos, necessitating surrogate markers for efficacy.

Purpose of the Study:

• To evaluate the opsonophagocytosis assay (OPA) as a surrogate marker for pneumococcal vaccine immunogenicity.
• To compare OPA with traditional antibody level measurements (ELISA).
• To highlight OPA's utility in specific populations and clinical scenarios.

Main Methods:

• Development and technical improvements of the opsonophagocytosis assay (OPA).
• Application of OPA for analyzing small sample volumes, including from children.
• Correlation analysis of OPA results with ELISA in various study groups.

Main Results:

• OPA replicates the in vivo antibody protection mechanism, offering a better reflection of vaccine-induced immunity.
• OPA has been optimized for speed, multiplexing, and small sample analysis.
• While ELISA and OPA correlate well in young children, discrepancies arise in elderly, immunodeficient populations, and with cross-reactive antibodies.

Conclusions:

• OPA serves as a valuable supplementary measure of pneumococcal vaccine immunogenicity, particularly when ELISA shows limitations.
• Standardization efforts are underway to further enhance the applicability and reliability of OPA.
• OPA is crucial for assessing vaccine efficacy in contexts where placebo-controlled trials are not feasible.